For the quarter ending 2025-09-30, SGMO had -$9,316K decrease in cash & cash equivalents over the period. -$28,562K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -34,930 | -50,583 |
| Depreciation and amortization | 989 | 2,013 |
| Amortization in operating lease right-of-use assets | 909 | 1,808 |
| Stock-based compensation | 2,127 | 4,822 |
| Deferred income tax benefit | 0 | - |
| Impairment of long-lived assets | 0 | 0 |
| Accretion of discount on marketable securities | 0 | 0 |
| Other | 0 | -35 |
| Interest receivable | 0 | 0 |
| Accounts receivable | 151 | -154 |
| Prepaid expenses and other assets | 1,836 | 1,389 |
| Refundable research income tax credits | 0 | 0 |
| Accounts payable and other accrued liabilities | 3,999 | 301 |
| Accrued compensation and employee benefits | 1,717 | 764 |
| Lease liabilities | -1,337 | -2,262 |
| Other non-current liabilities | 15 | 30 |
| Deferred revenues | 0 | - |
| Net cash used in operating activities | -28,498 | -44,307 |
| Maturities of marketable securities | 0 | 0 |
| Proceeds from sale of marketable securities | 0 | 0 |
| Proceeds from sale of assets classified as held for sale | 0 | 0 |
| Purchases of property and equipment | 64 | 24 |
| Net cash (used in) provided by investing activities | -64 | -24 |
| Proceeds from at-the-market offering, net of offering expenses | 19,576 | 17,627 |
| Proceeds from issuance of common stock, net of offering expenses | -106 | 21,589 |
| Taxes paid related to net share settlement of equity awards | 267 | 2,647 |
| Proceeds from issuance of common stock under employee stock purchase plan | 1 | 179 |
| Net cash provided by financing activities | 19,204 | 36,748 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 42 | 4,009 |
| Net decrease in cash, cash equivalents, and restricted cash | -9,316 | -3,574 |
| Cash and cash equivalents at beginning of period | 43,418 | - |
| Cash and cash equivalents at end of period | 30,528 | - |
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)